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Abstract The premature ageing Ataxia Telangiec-
tasia (AT) and Werner syndromes (WS) are
associated with accelerated cellular ageing. Young
WS fibroblasts have an aged appearance and acti-
vated p38 MAP kinase, and treatment with the p38
inhibitor SB230580 extends their lifespan to within
the normal range. SB203580 also extends the repli-
cative lifespan of normal adult dermal fibroblasts,
however, the effect is much reduced when compared
to WS cells, suggesting that WS fibroblasts undergo a
form of stress-induced premature senescence (SIPS).
A small lifespan extension is seen in AT cells, which
is not significant compared to normal fibroblasts, and
the majority of young AT cells do not have an aged
appearance and lack p38 activation, suggesting that
the premature ageing does not result from SIPS. The
lack of p38 activation is supported by the clinical
manifestation, since AT is not associated with
inflammatory disease, whereas WS individuals are
predisposed to atherosclerosis, type II diabetes and
osteoporosis, conditions known to be associated with
p38 activation.
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Introduction
Ataxia Telangiectasia (AT) is a multi-system human
genetic syndrome caused by mutations in the ATM
gene (Savitsky et al. 1995) that results in progressive
neurodegenerative dysfunction, a predisposition to
cancer, immune deficiency, and genome instability,
with a hallmark of onset in early childhood (Crawford
1998). In addition, individuals with AT have features
reminiscent of premature ageing, such as grey hair,
wrinkled skin, skin atrophy and sclerosis, and AT has
been described as a segmental progeroid-like syn-
drome (Barzilai et al. 2002; Hofer et al. 2005;
Rotman and Shiloh 1997; Wood et al. 2001; Wong
et al. 2003). At a cellular level, fibroblasts derived
from individuals with AT undergo premature repli-
cative senescence, manifested by a shortened in vitro
lifespan and a reduced colony forming ability
(Elmore and Swift 1976; Hoar 1975; Shiloh et al.
1982; Tchirkov and Lansdorp 2003; Vaziri et al.
1997).
Werner syndrome (WS) is caused by mutations in
the WRN gene and affected individuals show the
premature onset of several clinical features of old
age, including cataracts, skin atrophy, hair-greying
and soft tissue calcification, together with age-related
diseases such as type II diabetes, atherosclerosis and
osteoporosis (Martin et al. 1999). WS is also associ-
ated with genomic instability and a high incidence of
cancer. The age of diagnosis is often in the early
teens as individuals lack the pubertal growth spurt.
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Associated with premature ageing, accelerated cellu-
lar replicative senescence is found in WS with over
90% of WS fibroblast cultures having an in vitro life-
span of \25 population doublings (PDs) (Tollefsbol
and Cohen 1984).
Replicative senescence in normal human fibro-
blasts results from the progressive loss of telomeric
repeats at the ends of chromosomes due to the
inability of the DNA replication machinery to
efficiently replicate the 50 ends of linear chromo-
somes (Harley et al. 1990). Thus, it is formally
possible that the accelerated senescence seen in AT
and WS cells is due to accelerated telomere erosion
or a change in the threshold at which telomeres are
sensed by the cell as ‘critically short’ and thus trigger
senescence. Initial evidence suggested that telomere
erosion rates were elevated in WS cells (Schulz et al.
1996), however, more recent data has shown that the
accelerated cellular senescence seen in WS is not
associated with an increased rate of telomere erosion
per cell division (Baird et al. 2004). AT fibroblasts
also appear to have an elevated rate of telomere
erosion compared with normal cells (Tchirkov and
Lansdorp 2003; Vaziri et al. 1997), and telomeres
were found to be shorter in fibroblasts and peripheral
blood lymphocytes isolated from AT compared to
aged-matched normal individuals (Metcalfe et al.
1996; Pandita et al. 1995; Vaziri et al. 1997; Xia
et al. 1996). Treatment of AT cells with a specific
anti-oxidant appeared to reduce the telomere erosion
rate considerably, however, this was accompanied by
only a small increase in replicative lifespan (Tchirkov
and Lansdorp 2003). These data, taken together, seem
to suggest that in AT cells there is an increased rate of
telomere shortening, but this may not lead to the
reduced replicative cellular lifespan.
The AT and WS fibroblasts early in their replica-
tive lifespan are reported to show an altered,
enlarged, cellular morphology due to the presence
of extensive networks of F-actin stress-fibres (Davis
et al. 2005; McKinnon and Burgoyne 1985), and
resemble normal fibroblasts that have undergone
stress-induced premature senescence (SIPS) as a
result of oncogenic ras expression or arsenite treat-
ment (Deng et al. 2004; Guay et al. 1997; Huot et al.
1997; Wang et al. 2002). These features of SIPS can
result from activation of the stress-associated p38a
MAP kinase as the use of the p38 selective inhibitor
SB203580 prevents ras-induced senescence in human
BJ fibroblasts (Deng et al. 2004; Wang et al. 2002).
Activation of p38 leads to the stabilisation of the
cyclin-dependent kinase inhibitor p21WAF1 and sub-
sequent cell cycle arrest, and also leads to the
phosphorylation of the small heat shock protein
HSP27 resulting in stress fibre formation (Deng et al.
2004; Haq et al. 2002; Kim et al. 2002).
Recent work has shown that WS fibroblasts have a
normal lifespan and cellular morphology when
treated with the p38 inhibitor SB203580; in effect
SB203580 prevents the accelerated ageing that is a
hallmark of WS cells (Davis et al. 2005). Thus, the
accelerated ageing is thought to be due to SIPS, and
the p38 signalling pathway is activated in cultures of
young WS cells. The SIPS seen in WS cells may be
driven by replicative stress as the WRNp is a DNA
helicase associated with the replication fork, and a
high degree of replication fork stalling is seen in WS
cells (Rodriguez-Lopez et al. 2002; Pichierri and
Franchitto 2004; Davis and Kipling 2007).
ATM, the protein mutated in AT, is the primary
checkpoint kinase in response to DNA damage
(Kastan and Lim 2000; Pandita 2002). It functions
as a part of a large multi-protein complex that
includes WRN, and is thought play an important role
in the cellular response to replicative stress (Pichierri
and Franchitto 2004). These observations, and the
recent report that WRN cooperates with ATM to
implement the intra-S phase checkpoint in cells with
collapsed replication forks (Cheng et al. 2008),
suggests that the premature senescence seen in AT
cells may occur via a similar pathway to that in WS
cells. Thus, the reported similarities between young
AT cells, WS cells, and normal cells that have
undergone SIPS, and the observation that hTERT-
immortalised AT fibroblasts are able to undergo SIPS
via p38 activation in response to ionising radiation
despite the lack of ATM (Naka et al. 2004), suggest
the possible involvement of p38 and SIPS in the
accelerated ageing of AT fibroblasts.
The genome instability and increased pro-oxidant
state seen in AT provide a plausible trigger to activate
stress-signalling in AT cells and a possible involve-
ment for p38 in inducing the shortened replicative
lifespan and altered cellular morphology (Ball and
Xiao 2005; Barzilai et al. 2002). We therefore tested
the role of p38-transduced stress signalling in AT
using SB203580, a cytokine-suppressive anti-inflam-
matory drug whose major (but not sole) inhibitory
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target is p38 (Iwasa et al. 2003), together with
primary fibroblasts derived from dermal biopsies of
three separate AT patients. Although SB203580 was
effective in extending the replicative lifespan of AT
cells, the degree of lifespan extension was not
significantly more than that seen for normal adult
dermal fibroblasts, and it appears that, unlike in WS,
the accelerated senescence seen in AT fibroblasts is
not due to p38-induced SIPS.
Materials and methods
Cells and cell culture
Primary AT (GM05823, AG03058, and AG04405),
WS (AG05229, AG03141, and AG12795) and nor-
mal adult dermal (AG04552, AG09603, AG11020,
and AG13152) fibroblasts derived from biopsies of
human tissue were obtained from the Coriell Cell
Repository (Camden, NJ, USA). For added clarity,
when referring to the individual cell strains in this
paper a suffix (AT, WT or WS) has been added to the
designating code for Ataxia, wild-type, or Werner
cells, respectively. HCA2 cells that have been
immortalised by the ectopic expression of human
telomerase (herein called HCA2.trt cells) have been
described previously (Davis et al. 2006). All cells
were grown in Dulbecco’s modified Eagle medium
(DMEM) supplemented with 10% foetal calf serum
in an atmosphere containing 5% CO2, and passaged
every 4–5 days as described previously (Davis et al.
2003). PDs were calculated according to the formula:
PDs = log2(Nt/No), where Nt is number of cells
counted and No is number of cells seeded. For
experiments using p38 MAP kinase inhibitors, the
medium was supplemented with 10 lM SB203580
(Tocris Chemical Co. Bristol, UK) in DMSO, with
the medium changed daily. For controls, an equiva-
lent volume of DMSO was added to the medium.
SB203580 was used at 10 lM, a concentration used
routinely for studying the effects of SB203580 on p38
activity in cell biological systems (Davis et al. 2005;
Haq et al. 2002; Iwasa et al. 2003; Wang et al. 2002).
To activate the p38-signalling pathway using aniso-
mycin, HCA2.trt cells were plated onto 100 mm
dishes in DMEM and cultured for 2 days at 37C,
after which the cells were treated with 30 lM
anisomycin (Sigma, Poole, UK) for 45 min.
Immunofluorescence microscopy
Actin staining for immunofluorescence microscopy
was performed essentially as described (Huot et al.
1997). Briefly, the cells were plated into 35 mm
plastic dishes in DMEM and allowed to settle for
48 h. The cells were then washed in PBS, fixed in
3.7% paraformaldehyde for 20 min and permeabi-
lised with 0.1% Triton-X100 for 20 min. F-actin was
detected using fluorescein isothiocyanate-conjugated
(FITC)-conjugated phalloidin (33 lg/ml) (Sigma,
Poole, UK), diluted 1:50 in PBS for 30 min in the
dark, followed by washing in PBS.
Immunoblot analysis
Protein samples were prepared in lysis buffer
containing the phosphatase inhibitors NaF and
Na3VO4, separated on 12% sodium-dodecylsulphate/
polyacrylamide electrophoresis gels, electroblotted to
immobilon-P polyvinylidene difluoride or nitrocellu-
lose membranes (Millipore, Watford, UK) and anti-
bodies applied as described previously (Davis et al.
2003). The antibodies used were: mouse monoclonal
anti-HSP27 (G31), rabbit polyclonal anti-phospho-
(S82)-HSP27, anti-p38, anti-phospho(T180/Y182)-p38,
rabbit monoclonal anti-JNK1/2 (56G8), anti-phospho-
(T183/Y185)-JNK1/2, rabbit monoclonal anti-c-Jun
(60A8) (Cell Signalling, New England Biolabs,
Hitchin, UK). An enhanced chemiluminescence kit
(Amersham, Little Chalfont, UK) was used for
visualisation using HRP-coupled goat secondary
antibodies.
Results
Effects of SB203580 on the growth of normal
adult dermal fibroblasts
Previous data has shown that the accelerated ageing
seen in WS fibroblasts can be prevented by treatment
of the cells with the p38 inhibitor SB203580 with the
lifespan extension ranging up to 245% of replicative
lifespan (Davis et al. 2005; see, Fig. 1e). However,
the control cells used for the previous study were
long-lived MRC5 foetal lung fibroblasts, whereas the
WS cells were short-lived adult dermal cells. Thus,
better control strains would seem to be age- and
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Fig. 1 Growth of AT and
normal fibroblasts with or
without treatment with
SB203580. a–d Fibroblasts
were grown in standard
DMEM with no
supplementation (--),
with continual daily
supplementation with
SB203580 (-d-). Growth
measured as PDs versus
days. Only representative
growth curves are given for
AG13152(WT),
AG09603(WT),
AG03058(AT) and
AG04405(AT) cells. e Bar
chart comparing the effect
of SB203580 on the
experimental lifespan in
AT, normal and WS cells.
The lifespan extension for
untreated cells is given as
0%. For a definition of
experimental lifespan see
footnotes to Table 1
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tissue-matched adult dermal cells with a range of
replicative lifespans.
Thus, four strains of adult dermal fibroblasts were
used in this study that were chosen to have a range of
replicative lifespan from 21 to 50 PDs (Cristofalo
et al. 1998). To assess the effects of treatment of
primary adult fibroblasts with SB203580, cells were
grown continuously in the presence or absence of the
drug until they reached M1 senescence. The strain
with the shortest lifespan, AG13152(WT), has an
initial growth rate of 0.15 PDs/day and a replicative
lifespan of 24.0 PDs (Table 1; Fig. 1a). This growth
rate increases to 0.18 PDs/day in the presence of
SB203580, and the replicative lifespan to 29.5 PDs,
an increase in the experimental lifespan of *28%
with the culture initiated at 6 PDs. The strain with an
intermediate lifespan, AG11020(WT), has an initial
growth rate of 0.34 PDs/day and a replicative lifespan
of 41.7 PDs (Table 1). In the presence of SB203580,
these increase to 0.40 PD/day and 46.5 PDs, which is
an increase in replicative lifespan of *15% with the
culture initiated at 9 PDs. The longest-lived strain,
AG09603(WT), has an initial growth rate and lifespan
in untreated cells of 0.35 PDs/day and 47.8 PDs, that
increases to 0.43 PDs/day and 55.7 PDs when treated
with SB203580, an increase of replicative lifespan of
*25% with the culture initiated at 16 PDs (Table 1;
Fig. 1b). Finally, for a second short-lived normal
strain, AG04552(WT), an untreated growth rate and
lifespan of 0.15 PDs/day and 24.3 PDs increases to
0.19 PDs/day and 30.1 PDs with SB203580 treat-
ment, an increase in experimental lifespan of 41%
(Table 1). These increases in replicative lifespan for
normal cells are very small when compared to that
seen with WS cells (Fig. 1e; Davis et al. 2005).
However, the observation that SB203580 can extend
the replicative lifespan of normal adult dermal
fibroblasts suggests that adult dermal cells would
Table 1 Growth parameters for Ataxia Telangiectasia and normal dermal fibroblasts grown in the presence or absence of SB203580
Cell strain SB203580 treatment Maximum growth
rate (PD/day)a
Cellular lifespan
(PD)a
Average increase
in lifespan (%)b
AG03058(AT) - 0.15 ± 0.07 (3) 24.02 ± 2.84 (3)
? 0.31 ± 0.07 (3) 31.41 ± 4.23 (3) 61.8
P valuec P \ 0.024 P \ 0.034
AG04405(AT) - 0.36 ± 0.02 (4) 23.52 ± 0.64 (4)
? 0.40 ± 0.03 (4) 27.61 ± 0.82 (4) 28.3
P valuec P \ 0.025 P \ 0.00015
GM05823(AT) - 0.22 11.28
? 0.29 15.98 41.7
AG04552(WT) - 0.15 24.28
? 0.19 30.15 41.0
AG09603(WT) - 0.35 ± 0.01 (2) 47.76 ± 3.17 (2)
? 0.43 ± 0.01 (2) 55.73 ± 2.72 (2) 25.1
P valuec P \ 0.008 P [ 0.057
AG11020(WT) - 0.34 ± 0.004 (2) 41.74 ± 1.80 (2)
? 0.40 ± 0.042 (2) 46.55 ± 2.70 (2) 14.7
P valuec P \ 0.012 P [ 0.085
AG13152(WT) - 0.15 ± 0.0007 (2) 24.0 ± 3.01 (2)
? 0.18 ± 0.013 (2) 29.46 ± 2.96 (2) 28.1
P valuec P [ 0.03 P [ 0.10
a Mean ± SD; number of cultures in brackets (for GM05823(AT) and AG04552(WT) only a single culture used). The maximum
growth rate is based upon the linear part of the growth curve at early growth stages
b The experimental increase in lifespan achieved using SB203580 is calculated with reference to the starting PD: e.g., for
AG13152(WT) the lifespan is (27.4 PD-6 PD)/(24.3 PD-6 PD) = 1.41 9 control, or a 41% increase
c One-tailed t test
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appear to be the correct baseline upon which to
compare the effects of SB20580 on replicative
lifespan.
Effects of SB203580 on the growth of AT adult
dermal fibroblasts
Three strains of primary adult AT dermal fibroblasts
were used. The AG03058(AT) cells have an average
growth rate of 0.15 PDs/day and a replicative lifespan
of 24 PDs (Table 1; Fig. 1c). This lifespan is in
agreement with previous studies (Tchirkov and Lans-
dorp 2003). Treatment of AG03058(AT) cells with
SB203580 results in a significant increase in the
growth rate to 0.31 PDs/day. The average replicative
lifespan of the AG03058(AT) cells also shows a
significant increase to 31.4 PDs (Table 1). The exper-
imental increase in lifespan is approximately *62%,
starting at a PD of 12. AG04405(AT) cells have an
average growth rate of 0.36 PDs/day and a replicative
lifespan of 23.5 PDs (Table 1; Fig. 1d). This lifespan
is again in agreement with previous work (Tchirkov
and Lansdorp 2003). With SB203580 treatment, the
growth rate increases to 0.40 PDs/day and the lifespan
to 27.6 PDs. These increases, although small, are both
statistically significant. Finally, SB203580 treatment
results in an increase in growth rate and replicative
lifespan of GM05823(AT) cells (Table 1). The
increase in experimental replicative lifespan is 41.7%.
Examination of cellular morphology of AT, WS
and normal fibroblasts
One of the striking features of young WS fibroblasts
in culture is that they have an enlarged cellular
morphology with an extensive network of F-actin
stress fibres (Davis et al. 2005), and when young
AG05229(WS) cells are stained with phalloidin-FITC
the enlarged morphology and F-actin fibres can be
clearly seen (Fig. 2a). Continuous treatment of the
WS cells with SB203580 (Fig. 2b) alleviates this
cellular morphology and the cells now resemble
young normal cells (see, Fig. 2m, right panel). A
similar phenotype is seen with young AG03141(WS)
cells, where most of the control cells have extensive
F-actin stress fibres that are alleviated with contin-
uous SB203580 treatment (Fig. 2c, d).
It has been reported previously that primary
fibroblasts from AT individuals also have an enlarged
morphology compared to normal primary fibroblasts,
with an altered micro-filament array (McKinnon and
Burgoyne 1985), and thus the AT cells resemble WS
cells in this regard. The cells used in the previous
study included GM05823(AT) cells. In this work we
have examined the morphology of replicatively
young GM05823(AT) cells and stained them with
phalloidin-FITC to visualise the F-actin stress fibres.
In a young population of GM05823(AT) cells
(Fig. 2e), a few enlarged cells can be seen. However,
the majority of the cells have a small morphology
resembling young normal cells (Fig. 2m, right panel).
The actual ratio of large irregular cells was not
calculated, however, it is estimated to be\5%. When
the cells are treated with phalloidin-FITC to stain the
F-actin filaments (Fig. 2f), an extensive network of
stress fibres is observed only in the large irregular
cells. Growth of GM05823(AT) cells in medium
supplemented with SB203580 has little effect on the
size distribution of the cells, however, the large
irregular cells do not appear as granular in appear-
ance (Fig. 2g). When stained with phalloidin-FITC
(Fig. 2h) the enlarged cells still have numerous
F-actin stress fibres. A similar situation is found for
young AG03058(AT) cells (Fig. 2i, j) with the cell
populations having a few enlarged cells with numer-
ous stress fibres, but most of the cells having a small
young-looking morphology. As with GM05823(AT)
cells, the morphology distribution is not affected by
SB203580 treatment (Fig. 2k, l). Finally, with young
AG04405(AT) cells, very few cells have an enlarged
morphology and SB203580 treatment has no effect
on this morphology (data not shown).
We also examined normal adult dermal fibroblast
strains using both phase contrast and phalloidin-FITC
staining. With young AG11020(WT) cells (Fig. 2m),
essentially the same pattern is seen as for the AT cells
of a similar small number of enlarged cells with
extensive stress fibres, with the majority of the cells
having a normal morphology. Again SB203580
treatment has little effect on these cells (Fig. 2n). A
similar pattern is seen in all the normal adult
fibroblast strains used in this study (data not shown).
When the AT, WS and normal adult dermal
fibroblasts reach M1 senescence, the majority of the
cells have the enlarged morphology with extensive
F-actin stress fibres typical of senescent cells, for
both untreated cells and cells grown continuously in
SB203580 (data not shown and, Davis et al. 2005).
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As normal cells at the end of their replicative lifespan
have F-actin stress fibres that are insensitive to
SB203580 treatment, this suggests that the large
irregular cells seen in the young populations in AT
and WT cells have undergone replicative senescence
through the normal ‘‘stochastic’’ processes, perhaps
Fig. 2 Observation of cellular morphology and F-actin stress
fibres in AT, WS and normal fibroblasts. For morphology, live
cells were examined by phase contrast microscopy (e, g, i, k).
For examination of stress fibres cells were fixed and stained
with phalloidin-FITC (a, b, c, d, f, h, j, l, m, n). For each panel,
the cell type and PD values are given: note that the control and
SB203580 treated cells were grown for the same lengths of
time so the PD value for the treated cells will be slightly higher
due to slightly more rapid growth and the control cells
maintained their morphology until they reached senescence. A
suffix.c are control cells and a suffix.sb are cells treated with
SB203580. Panels m and n are composites of two different
representative views of the phalloidin stained cells. Black bars
are 100 lm; white bars are 50 lm
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dependent upon telomere erosion, and that this
senescence is independent of p38.
Characterisation of stress kinase effector
pathways
To assess the activation status of p38 in normal and
AT fibroblasts, proteins were extracted from young
cells grown in the presence or absence of SB203580,
and Western blots were probed with antibodies for
p38 and its activating phosphorylation (Fig. 3a).
Little activation of p38 is seen in either normal
AG09603(WT) cells or in AG03058(AT) AT cells, as
indicated by the low levels of phosphorylated p38.
There is also very little phosphorylation of the small
heat shock protein HSP27 at the Ser82 site in these
cells. As a control, Fig. 3a demonstrates that
HCA2.trt cells that have been stimulated with
anisomycin, which is known to activate the p38
pathway, show high levels of both phosphorylated
p38 and HSP27 (Fig. 3a). As HSP27 is a major
downstream target of the p38 pathway via the kinase
MK2 (Huot et al. 1997), these data strongly suggest
that the p38 kinase signalling pathway is not
significantly activated in AT cells. In contrast, p38
is activated in young AG03141(WS) cells (Fig. 3b)
and, interestingly, SB203580 treatment appears to
prevent this activation for reasons that are unclear
(Davis et al. 2005). Activation of the p38 pathway is
also seen in young AG05229(WS) cells (Davis et al.
2007). The activated p38 results in increased levels of
phosphorylated HSP27 in the WS cells, which is
prevented in cells treated with SB203580 (Davis
et al. 2005, 2007).
The c-Jun N-terminal kinases (JNKs) are also
activated in response to stress (Davis 2000), so we
determined the level of activated JNKs in the AT and
normal cells (Fig. 3a). In untreated AG03058(AT)
cells, activated JNK1/2 is barely detectable. In
AG03058(AT) cells treated with SB203580, low
levels of the phosphorylated p46 versions of JNK1/2
are seen (Fig. 3a). These are the JNK1a1 and
JNK2a1 isoforms of JNK (Liu et al. 2004). The
increased amounts of activated JNK1/2 may reflect
the increased levels of JNK1/2 in the treated cells, or
may indicate that JNK1/2 are activated to a low level
in SB203580 treated cells. Interestingly, there is an
elevated level of p46 JNK activation in the normal
Fig. 3 Immunoblot analysis of proteins from cells grown in
the presence or absence of SB203580. a Protein lysates were
prepared from primary AG03058(AT) and AG09603(WT) cells
and from hTERT-immortalised HCA2 cells. b Protein lysates
were prepared from primary AG03141(WS) cells. Expression
levels were compared for phosphorylated p38 (p-p38), p38,
phosphorylated JNK1/2 (p-JNK1/2), JNK1/2, phosphorylated
HSP27 (p-HSP27), HSP27 and c-Jun. For JNK1/2 the p46 and
p54 kDa versions are indicated, and phosphorylated c-Jun
versions are shown (p-c-Jun). For each blot an equal amount
(15 lg) of protein was loaded per sample
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cells as compared to the AT cells, although this is still
at a low level when compared to that seen in
anisomycin treated HCA2.trt cells. This low level of
JNK activation is confirmed by the low levels of
detectable phosphorylated forms of c-Jun in the AT
and normal cell strains compared to anisomycin
treated HCA2.trt cells (Fig. 3a).
Discussion
Normal human fibroblasts have a limited replicative
lifespan in culture before they enter an irreversible
non-dividing state termed M1 or senescence (Hayflick
and Moorhead 1961; Shay and Wright 2000). Cellular
senescence is not death, but resembles terminal
differentiation in that the cells have a morphology
and pattern of gene expression that differs markedly
from their dividing counterparts (Itahana et al. 2004;
Kipling et al. 2004). This replicative senescence has
been postulated to contribute to human ageing and
senescent cells have been found in many human
tissues during ageing (Davis and Kipling 2006; and
references therein). Cellular senescence may contrib-
ute to age-related degenerations due to reduced
proliferative capacity in tissues that require continu-
ous division throughout life and/or, due to the
deleterious features of senescent cells such as the
secretion of degradative enzymes and inflammatory
cytokines. However, the actual role, if any, of cellular
senescence in human ageing is disputed (Rubin 2002).
The study of human ageing is aided by model systems
that reflect upon aspects of the ageing process, the
so-called progeroid syndromes (Kipling et al. 2004;
Cox and Faragher 2007; Kudlow et al. 2007). In this
paper we describe results from growth experiments
using fibroblasts from two of these syndromes that
manifest accelerated cellular senescence, AT and WS.
Although replicative senescence in human fibro-
blasts is thought to result from the progressive loss
of telomeric DNA with ongoing cell division, the
premature senescence of WS fibroblasts is not due to
accelerated telomere shortening (Baird et al. 2004), but
appears to result from the activation of the stress-
induced p38 MAP kinase, and young WS fibroblasts
have an altered cellular morphology that resembles cells
having undergone SIPS (Davis et al. 2005). Treatment
of WS cells with the p38 kinase inhibitor SB203580
effectively prevents the accelerated ageing seen in WS
cells, suggesting that this premature ageing is indeed
due to SIPS. In addition, these data raise the possibility
that p38 inhibitors may one day provide therapeutic
options for WS individuals by preventing this acceler-
ated cellular ageing (Davis and Kipling 2006).
However, there are two possible criticisms of the
original study: firstly, the use of the foetal lung
cell strain MRC5 as a control for SB203580-induced
lifespan extension; secondly, the control cells had a long
replicative lifespan (Davis et al. 2005). As the WS cells
were short-lived adult dermal cells, it is possible that the
effects seen with SB203580 were due to a combination
of an adult dermal cell-specific effect and a short
lifespan. As normal human adult dermal fibroblasts have
a replicative lifespan ranging from approximately 25 to
70 PDs (Cristofalo et al. 1998), it is possible that
SB203580 treatment would have a similar effect on
short-lived normal cells as is seen for WS cells.
Therefore, in this study, we have used four normal
adult dermal fibroblast strains that have replicative
lifespans ranging from 24 to 48 PDs (Cristofalo et al.
1998). The lifespans of the short-lived normal strains
are at the upper range of the WS strains (Davis et al.
2005). For each cell strain, treatment with SB203580
extended their replicative lifespan, however, the
increases in experimental lifespan only ranged from
15 to 41%. This compares to an increase in experi-
mental lifespan for three WS strains of 100, 175 and
245% (see, Fig. 1e) (Davis et al. 2005). SB203580
treatment also increased the growth rate of the normal
cells by up to 30% (Table 1). By comparison, the
increased growth rate seen in SB203580-treated WS
cells was between 128 and 160% (Davis et al. 2005).
In addition, the majority of the young normal dermal
cells have a small cellular morphology lacking F-actin
stress fibres, and p38 was activated in these cells.
Finally, SB203580 treatment extends the experimen-
tal lifespan of HCA2 neonatal dermal fibroblasts by
41%, but has no effect on the cellular morphology,
and p38 is not activated in young HCA2 cells (Davis
et al. 2007). These combined data provide strong
supporting evidence that the effects of SB203580 on
WS cellular lifespan are mainly due to the loss of
WRN resulting in SIPS via p38 activation.
In addition to using normal adult fibroblasts, we
have extended this study to AT, a progeroid syn-
drome that is also associated with fibroblasts that are
reported to have an altered cellular morphology
characteristic of cells undergoing SIPS, and show
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accelerated replicative senescence. Treatment with
the p38 specific inhibitor SB203580 does increase the
replicative lifespan of AT cells, albeit only by
between 28 and 60% of experimental lifespan. The
increase in lifespan for two of the strains is within the
range seen for normal cells, however, the increased
lifespan seen in AG03058(AT) cells is intermediate
between that of normal and WS cells (see, Fig. 1e).
Finally, in contrast to previous reports (McKinnon
and Burgoyne 1985), we find that the cellular
morphology of young fibroblasts from three AT
individuals is essentially identical to that seen in
three normal adult dermal fibroblast strains, where
the cultures consist of a few enlarged cells with the
majority of the cells having a normal morphology.
This morphology is quite distinct to the morphology
seen in young WS fibroblasts. Daily treatment with
SB203580 had little effect on this morphology. This
lack of enlarged morphology and F-actin stress fibres
correlates well with the lack of p38 activation and
subsequent phosphorylation of HSP27 seen in both
AT and normal cells. In summary, the only pheno-
typic manifestation seen in the AT cells in this study
compared to normal adult dermal fibroblasts, was that
they all had an in vitro lifespan of \25 PDs, which
was in the range of the shortest lifespan seen for
normal cells. The data reported in this work strongly
suggest that the short replicative lifespan of AT cells
is not due to SIPS via p38 activation.
Both AT and WS are associated with accelerated
cellular senescence, however, the senescence mecha-
nism differs for each syndrome. Recent evidence
suggests that WRN cooperates with ATM to imple-
ment an intra-S phase checkpoint in cells with
collapsed replication forks, with WRN being required
for ATM activation (Cheng et al. 2008). The primary
sensor of stalled replication forks is ATR, which
recruits the MRN complex and RAD51 and RAD52,
with fork stalls being repaired via a homologous
recombination dependent process (Pichierri and
Franchitto 2004). The WRN protein appears to be
required to resolve the recombinational intermediate,
an idea supported by the observation that the growth
defect of WS cells can be corrected by ectopic expres-
sion of the bacterial resolvase RusA (Rodriguez-Lopez
et al. 2007). This resolution creates a double-strand
break (DSB) that is then repaired in an ATM-
dependent fashion (Shiloh 2003). DSBs are also
created as a result genomic insults such as oxidative
stress or c irradiation, and by cellular processes such
as V(D)J recombination or telomere replication
(Shiloh 1997; Verdun and Karlseder 2006). Such
DSBs are also repaired in an ATM-dependent
fashion, but this repair does not appear to require
WRN to activate ATM (Bolderson et al. 2004; Cheng
et al. 2008). In other words, WRN and ATM are
epistatic in the repair of DSBs induced by replication
fork stalls, but DSBs resulting from other processes
are repaired independently of WRN (Fig. 4). This
model predicts that cells lacking WRN would
undergo replication fork blockage and cell cycle
arrest in an ATM-independent fashion, whereas in
cells lacking ATM there would be an increase in
DSBs leading to senescence, perhaps dependent upon
ATR (Herbig et al. 2004).
Indeed, WS cells are hyper-sensitive to a certain
type of DNA damaging agent that blocks replication
fork progression, and there is a high level of
replication fork stalling (Rodriguez-Lopez et al.
2002). As WRN is required for the recombinational
resolution of fork stall repair, in WS cells there is a
failure to restart the replication fork. This failure
results in a condition termed ‘replication stress’ that
then activates p38 resulting in cellular senescence
(Davis et al. 2007; Pichierri and Franchitto 2004;
Rodriguez-Lopez et al. 2002). As this replication
stress is ‘stochastic’ this would lead to premature
senescence in a subset of WS cells at each division,
Fig. 4 Model for the role of WRN and ATM in telomere
replication and V(D)J rejoining, and in response to collapsed
replication forks
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exactly what is observed (Baird et al. 2004; Faragher
et al. 1993). This idea is supported by the observation
that resolution of the recombinational blockage by
ectopic expression of the bacterial resolvase RusA
corrects the growth defect of WS cells (Rodriguez-
Lopez et al. 2007). Once the blockage has been
resolved the DSB can be repaired by ATM action,
and the replication fork can proceed.
In contrast to WS, a significant feature of AT cells is
a high incidence of telomere fusions (Pandita et al.
1995). The replication of telomeres by DNA polymer-
ases leads to the exposure of single stranded DNA that
is detected by Mre11 and RPA, which then activate
ATR, so as to initiate completion of telomere replica-
tion. This leads to the production of a DSB with a short
30 overhang that triggers an ATM-dependent produc-
tion of the t- and D-loop structures that protect the
telomere end (see, Verdun and Karlseder 2006, for
details). This model predicts that loss of ATM would
stall telomere replication resulting in the production of
DSBs. It may be the generation of these DSBs that
leads to the telomere fusions seen in AT cells. These
telomere fusions then lead to increased rates of
apoptosis and/or cellular senescence.
This model then provides a possible explanation for
the clinical manifestation in AT and WS. Features in
common include, premature grey hair, alopecia, skin
atrophy and sclerosis, phenotypes which may result
from the build-up of senescent cells in tissues, or be
due to reduced renewal ability of these tissues due to
replicative exhaustion. If so, then the actual mecha-
nism by which these cells undergo accelerated ageing
may not be directly relevant, the important point being
the actual presence and build-up of the senescent cells
(Bird et al. 2003; Hofer et al. 2005; Kipling et al.
2004). In WS, this accelerated senescence results from
stress-induced p38 activation, whereas in AT it is due
to the high incidence of telomere fusions.
However, there are clinical features that distinguish
the two syndromes; in AT it is immunodeficiency and
ataxia, whereas in WS it is inflammatory diseases such
as atherosclerosis, type II diabetes, and osteoporosis.
Here the actual mechanism underlying the accelerated
cellular senescence may have clinical relevance.
Although the actual aetiology of the ataxia is not fully
understood, the immunodeficiency in AT appears to be
due to the inability of T cell expansion, resulting from
lack of ATM leading to inappropriate V(D)J recom-
bination in T cell receptor and immunoglobulin genes
(Kojis et al. 1991), acting in concert with the telomere
fusion induced senescence. The inflammatory pheno-
types seen in WS, however, may result from the
activation of p38. Inflammatory diseases are associ-
ated with up-regulation of inflammatory cytokines
such as IL-1 and TNFa, both of which are downstream
in the p38-signalling pathway, and WS individuals have
elevated TNFa levels in vivo (Davis and Kipling 2006;
Yokote et al. 2004). Thus, the presence of activated p38
in WS cells may predispose individuals to inflammatory
disease, and the lack of p38 activation in young AT cells
may reflect the in vivo manifestation, as AT is not
reported to be associated with inflammatory diseases
(Crawford 1998; Lavin and Shiloh 1997; Rotman and
Shiloh 1998).
In summary, the results described in this study
provide indirect support for the hypothesis that the
prevention of accelerated ageing in WS fibroblasts by
SB203580 is due inhibition of p38, and suggest a role
for SIPS p38 activity in the clinical features of WS. If
premature ageing of cells and p38 activation do
underlie the accelerated ageing of WS individuals,
then the recent development of a fully reflective mouse
model of WS (Chang 2005) now makes future studies
possible as to whether p38 inhibitors will be effective
as therapeutic agents in a premature ageing disease.
Some of these p38 inhibitors have undergone phase II
and III clinical trials for inflammatory disease (Sak-
latvala 2004). In addition, we have synthesised and
tested some of these inhibitors for their efficacy to
inhibit p38 in WS cells, and studies as to their
effectiveness in ameliorating WS cellular phenotypes
are ongoing (Bagley et al. 2006, 2007, 2008).
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